Amylin drugs
Amylin is a hormone the pancreas releases with insulin. These drugs are built on it, alone or with a GLP-1 drug.
In this group
- PramlintideSymlin: a lab-made version of amylin, the hormone released with insulin, injected before each major meal.Approved by the FDA in 2005 for diabetes alongside mealtime insulin, as Symlin, and now listed by the FDA as discontinued.
- CagrilintideA long-acting version of amylin, tested as a once-a-week injection.Not approved by the FDA, and in phase 3 trials on its own as of October 2026.
- CagriSemaSemaglutide, the drug in Wegovy and Ozempic, paired with an amylin drug in one weekly injection.Not approved by the FDA as of October 2026; Novo Nordisk filed for approval in December 2025.
- AmycretinOne molecule that acts on both GLP-1 and amylin receptors, now also called zenagamtide.Not approved by the FDA, and in phase 3 trials as of October 2026.
- PetrelintideAn amylin drug built on human amylin and tested as a weekly injection.Not approved by the FDA, and in phase 3 trials as of October 2026.
Related: The GLP-1 family
Get an early invite to Tidepath
The app isn't in the App Store yet. Leave your email for an early invite, and tips for your first month.
Get an early invite, tips and occasional news from Tidepath. Unsubscribe anytime. Privacy · Health data privacy · Sender and contact details